Contact | Newsletter | Créer votre compte
(Mise à jour 17:45) Epidémie de choléra dans le nord de la Zambie Neuf Palestiniens meurent de grippe H1N1 en Cisjordanie Pakistan: un sirop contre la toux toxique tue 24 personnes Greffe simultanée de cinq organes: mise au point de l'Académie de chirurgie Un meilleur usage du médicament économiserait 500 milliards de dollars Aluminium dans les vaccins: nouvel apppel aux autorités sanitaires Les secrets dévoilés de l'intestin irritable OGM: Séralini accuse l'autorité sanitaire européenne de faute professionnelle Cholestérol: rappel de génériques de Lipitor aux Etats-Unis Le virus de la variole détecté dans un corps gelé en Sibérie Coronavirus: quatre nouveaux cas d'infection, selon l'OMS Attention aux collyres pour les tout-petits Les hépatites virales mal combattues malgré un million de victimes par an Méningite B : un premier vaccin autorisé en Europe Sida: l'ONU donne des raisons d'espérer Surconsommation d'antibiotiques: mieux encadrer les prescriptions Soudan: vaste campagne de vaccination contre la fièvre jaune au Darfour France - Une partie du monde médical en grève Le Brésil va tester un moustique vacciné contre la dengue La pneumonie, principale cause de mortalité infantile selon l'Unicef
  Home > Actualités médicales > Medical news
 
  MARINE: Ethyl-EPA reduces triglyceride levels without raising LDL cholesterol
Dublin, Ireland and Mystic, CT - Ethyl eicosapentaenoic acid (EPA), a semisynthetic derivative of omega-3 fatty acids, significantly lowers triglyceride levels in patients with very high triglyceride levels without significantly increasing LDL-cholesterol levels. ... [suite] 0Commentaire(s)
Par : Moderateur : Asirem Le : 2010-12-01 à: 20:35:35

  SHARP: Ezetimibe/simvastatin combo cuts atherosclerotic and vascular events in kidney disease patients
Denver, CO - Final results of the Study of Heart and Renal Protection (SHARP) trial show that cholesterol lowering with a combination of simvastatin and ezetimibe (Vytorin, Merck) in patients with kidney disease significantly reduced the risk of "major atherosclerotic events" ... [suite] 0Commentaire(s)
Par : Moderateur : Asirem Le : 2010-11-22 à: 11:05:45

  New Drug Appears To Overcome Resistance In Ovarian Cancer
A new drug recently approved in the US as a first-line treatment for relapsing forms of multiple sclorosis, appears also to kill ovarian cancer cells in a way that overcomes drug resistance, a major obstacle to curing ovarian cancer; the breakthrough discovery still has to be confirmed by trials, but because the drug, code-named FTY720 (also known as fingolimod), is already approved for other reasons, the Australian and Chinese research team said it should not take as long to get to market as a ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-11-15 à: 20:26:44

  Stop Looming Medicare Cuts To Physician, AMA Urges Congress
The American Medical Association urges Congress to preserve health care for seniors by blocking a sizeable Medicare cut to doctors. If nothing is done by December 1, doctors will be receiving 25% less from Medicare, which will have negative repercussions for the elderly health care, the AMA (American Medical Association) announced today. ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-11-15 à: 20:23:42

  Vitamin-D analog could lower renal risk in diabetic nephropathy
Groningen, the Netherlands - The addition of a vitamin-D-receptor activator, paricalcitol (Zemplar, Abbott Laboratories), to therapy in patients with diabetic nephropathy reduces albuminuria, a new study published online November 3, 2010 in the Lancet has shown ... [suite] 0Commentaire(s)
Par : Moderateur : Asirem Le : 2010-11-05 à: 11:56:40

  Dabigatran Q&A: The who, when, and how for switching, starting, and stopping the new oral anticoagulant
New York, NY - Dabigatran (Pradaxa, Boehringer Ingelheim) will be available in both Canadian and US pharmacies as of today for its newly approved indication: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, the manufacturer, Boehringer Ingelheim, has announced [1]. The company has also said the drug will be priced at a "wholesale-acquisition" cost of $6.75 per day, lower than expected based on the up to $12/day price in markets where it is alre ... [suite] 0Commentaire(s)
Par : Moderateur : Asirem Le : 2010-11-03 à: 20:57:55

  Protein shows promise as a therapeutic target in pulmonary arterial hypertension
Montreal, QC - A protein implicated previously in leukemia, lymphomas, and prostate cancer might one day play a role in not only identifying individuals at risk for pulmonary arterial hypertension but also in their treatment, according to the results of a new study. ... [suite] 0Commentaire(s)
Par : Moderateur : Asirem Le : 2010-10-31 à: 19:57:25

  Sepsis Linked To Mental And Physical Decline In Older Patients
A new US study found that older patients who survived severe sepsis were more likely to experience signficant mental and physical decline, in some cases not unlike dementia, and suggested this was an unrecognized public health problem with major implications not only for patients but also for families and healthcare providers. ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-10-27 à: 20:13:50

  Falling In Love Hits The Brain Like Cocaine Does
Falling in love affects intellectual areas of the brain and triggers the same sensation of euphoria experienced by people when they take cocaine, researchers from Syracuse University reveal in an article in Journal of Sexual Medicine. The study, called "The Neuroimaging of Love" found that several euphoria-inducing chemicals, such as vasopression, adrenaline, oxytocin and dopamine are released in 12 areas of the brain that work simultaneously. ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-10-27 à: 20:10:14

  The Impact Of Chronic Diseases On Patients Also Depends On Their Perception Of The Disease
Researchers at the University of Granada have developed a test to measure and assess chronic patients' cognitive representation of their disease. This advance will enable the development of clinical psychological treatments much more efficient than those currently employed. ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-10-23 à: 21:58:06

Archives : Début ...3 4 5 6 7 8 9 10

Actuellement sur la page : 8

Partenaires
&
Amis d'Actumed

Actualités médicales Formation médicale Autres rubriques
© 2009-2012 / ACTUMED Tous droits réservés